β-干扰素治疗多发性硬化症：作用机制

Interferon beta in the treatment of multiple sclerosis: mechanisms of action.

作者信息

Yong V W, Chabot S, Stuve O, Williams G

机构信息

Department of Oncology and Clinical Neurosciences, Faculty of Medicine, University of Calgary, Alberta, Canada.

出版信息

Neurology. 1998 Sep;51(3):682-9. doi: 10.1212/wnl.51.3.682.

DOI:10.1212/wnl.51.3.682

PMID:9748010

Abstract

Interferon beta (IFN-beta) has been shown in several clinical trials to have efficacy in MS. Its mechanism of action, however, remains unclear. In this review, several biological activities of IFN-beta are highlighted, including its inhibitory effects on proliferation of leukocytes and antigen presentation. Furthermore, IFN-beta may modulate the profile of cytokine production toward that of the anti-inflammatory phenotype, and this appears to occur in the systemic circulation and within the CNS. Finally, IFN-beta can reduce T-cell migration by inhibiting the activity of T-cell matrix metalloproteinases. These activities are likely to act in concert to account for the mechanism of IFN-beta in MS.

摘要

在多项临床试验中已表明，β-干扰素（IFN-β）对多发性硬化症（MS）具有疗效。然而，其作用机制仍不清楚。在本综述中，重点介绍了IFN-β的几种生物学活性，包括其对白细胞增殖和抗原呈递的抑制作用。此外，IFN-β可能会将细胞因子产生的谱型调节为抗炎表型，这似乎发生在体循环和中枢神经系统内。最后，IFN-β可通过抑制T细胞基质金属蛋白酶的活性来减少T细胞迁移。这些活性可能协同作用，以解释IFN-β在MS中的作用机制。